NES BIOTECHNOLOGY Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NES BIOTECHNOLOGY Co., Ltd. - overview
Established
2019
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2019, NES BIOTECHNOLOGY Co. , Ltd. operates as a biotechnology company that develops therapeutic kits such as Nucleic Acid Delivery Kits, Antibody Delivery Kits, and Protein Delivery Kits to diagnose and treat infectious diseases, cancers, and hereditary diseases. In July 2021, NES BIOTECHNOLOGY raised KRW 3 billion in venture funding from Genomictree, Inc.
As of July 2023, Kangseok Lee is the Chief Executive Officer (CEO) of the company. NES BIOTECHNOLOGY Co. , Ltd. specializes in the development of therapeutic biomolecules for many kinds of treatments, with nano blocks incorporated in their formulation.
The company transports bioactive molecules by using a delivery system based on gold nanoparticles. This method enables medical professionals to safely administer personalized nucleic acids, proteins, and antibodies to cell lines and animals. Furthermore, the firm's technology acts as a shield for DNA, RNA, and protein therapeutics during transport to their intended targets, ensuring safe and efficient delivery into the specific cells for effective treatment.
Current Investors
KB Investment, Korea Tech Incubator for Startup, Genomictree, Inc.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic Equipment, Pharmaceutical Research & Development
Website
www.nesbiotech.com
Verticals
HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.